Table 1. Demographic characteristics, past medical history, and baseline cancer status of the study population.
| Variable | Total (n=122) | ADT+abiraterone (n=102) | ADT+docetaxel (n=20) | p-value | |
|---|---|---|---|---|---|
| Age, y | 68.9±8.3 | 69.5±8.3 | 65.8±7.8 | 0.065 | |
| BMI (kg/m2) | 23.9±2.9 | 23.8±3.0 | 24.7±2.4 | 0.199 | |
| ECOG PS | 0.777 | ||||
| 0 | 94 (77.0) | 79 (77.5) | 15 (75.0) | ||
| ≥1 | 28 (23.0) | 23 (22.5) | 5 (25.0) | ||
| DM | 23 (18.9) | 18 (17.6) | 5 (25.0) | 0.684 | |
| Hypertension | 58 (47.5) | 44 (43.1) | 14 (70.0) | 0.086 | |
| PSA at initial diagnosis (ng/mL) | 142.7 (54.7–626.3) | 150.0 (55.5–651.0) | 100.0 (52.7–604.7) | 0.596 | |
| PSA at metastasis (ng/mL) | 151.6 (57.4–626.3) | 161.6 (62.6–664.8) | 86.0 (44.2–500.0) | 0.292 | |
| Testosterone at metastasis (ng/mL) | 3.3 (2.6–4.8) | 3.7 (2.7–5.7) | 2.8 (2.6–3.4) | 0.192 | |
| Clinical tumor stage | 0.083 | ||||
| ≤T3a | 16 (13.1) | 10 (9.8) | 6 (30.0) | ||
| T3b | 42 (34.4) | 36 (35.3) | 6 (30.0) | ||
| T4 | 59 (48.4) | 51 (50.0) | 8 (40.0) | ||
| Unknown | 5 (5.1) | 5 (4.9) | 0 (0.0) | ||
| Gleason score | 0.695 | ||||
| ≤8 | 60 (49.2) | 51 (50.0) | 9 (45.0) | ||
| ≥9 | 59 (48.4) | 49 (48.0) | 10 (50.0) | ||
| Unknown | 3 (2.5) | 2 (2.0) | 1 (5.0) | ||
| % Of positive cores | 91.7 (60.7–100.0) | 90.3 (58.3–100.0) | 95.8 (71.1–100.0) | 0.215 | |
| Max. rate (%) | 90.0 (75.0–100.0) | 90.0 (75.0–100.0) | 91.9 (80.6–100.0) | 0.285 | |
Values are presented as means±standard deviations, medians (interquartile ranges), or numbers (%), unless otherwise indicated.
ADT: androgen-deprivation therapy, BMI: body mass index, DM: diabetes mellitus, ECOG PS: Eastern Cooperative Oncology Group performance status, PSA: prostate-specific antigen, Max: maximum.